CDKN2A and neoplasm: For instance, cases with OS < 6 months significantly had a higher KRAS mutation abundance in ctDNA (P = 0.006), higher TP53 abundances in both tumor (P = 0.035) and blood (P < 0.001), and higher CDKN2A abundances in both tumor (P = 0.040) and blood (P = 0.032).